Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
NCT06348108Phase 1Recruiting
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Bispecific Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of iberdomide and talquetamab in multiple myeloma (MM) (3 arms). Primary endpoints: Treatment-Emergent Adverse Events, Dose-Limiting Toxicities up to 3 years and 2 more. Started Jul 2025; status: recruiting.
02
Drugs
iberdomidetalquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06348108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06348108.